Patents by Inventor Ermanno Gherardi

Ermanno Gherardi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MET receptor agonist proteins
    Patent number: 10435450
    Abstract: Disclosed are proteins derived from the HGF/SF which are able to induce activation of the tyrosine kinase receptor MET and their uses, in particular to promote tissue regeneration. Further disclosed are nucleic acid molecules coding such protein, expression vectors containing such nucleic acid molecule, host cells containing such expression vectors, and related compositions.
    Type: Grant
    Filed: January 21, 2016
    Date of Patent: October 8, 2019
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT PASTEUR DE LILLE, UNIVERSITA' DEGLI STUDI DI PAVIA, UNIVERSITÉ DE LILLE
    Inventors: Jerome Vicogne, Oleg Melnyk, Nathalie Ollivier, Eric Adriaenssens, Berenice Leclercq, Claire Simonneau, Giovanni De Nola, Ermanno Gherardi, Hugo De Jonge
  • MULTIMERIC COMPOUNDS OF A KRINGLE DOMAIN FROM THE HEPATOCYTE GROWTH FACTOR / SCATTER FACTOR (HGF/SF)
    Publication number: 20180008723
    Abstract: Disclosed are multimeric compounds of K1 domains from the Hepatocyte Growth Factor/Scatter Factor (HGF/SF) being able to induce activation of the tyrosine kinase receptor MET and their uses.
    Type: Application
    Filed: January 21, 2016
    Publication date: January 11, 2018
    Inventors: Jerome VICOGNE, Oleg MELNYK, Nathalie OLLIVIER, Eric ADRIAENSSENS, Berenice LECLERCQ, Claire SIMONNEAU, Giovanni DE NOLA, Ermanno GHERARDI, Hugo DE JONGE
  • MET RECEPTOR AGONIST PROTEINS
    Publication number: 20170369545
    Abstract: Disclosed are proteins derived from the HGF/SF which are able to induce activation of the tyrosine kinase receptor MET and their uses, in particular to promote tissue regeneration. Further disclosed are nucleic acid molecules coding such protein, expression vectors containing such nucleic acid molecule, host cells containing such expression vectors, and related compositions.
    Type: Application
    Filed: January 21, 2016
    Publication date: December 28, 2017
    Inventors: Jerome VICOGNE, Oleg MELNYK, Nathalie OLLIVIER, Eric ADRIAENSSENS, Berenice LECLERCQ, Claire SIMONNEAU, Giovanni DE NOLA, Ermanno GHERARDI, Hugo DE JONGE
  • Antibodies directed to the receptor tyrosine kinase c-Met
    Patent number: 9169329
    Abstract: The present invention relates to antibodies that specifically bind to unprocessed c-Met present on the surface of tumor cells. These antibodies are useful in the diagnosis and treatment of cancer or as agents for delivering moieties to cancer cells. The antibodies of the present invention may also be used in therapy in combination with chemotherapeutics or anti-cancer agents.
    Type: Grant
    Filed: June 1, 2011
    Date of Patent: October 27, 2015
    Assignees: Ludwig Institute for Cancer Research, Monash University
    Inventors: Terrance Grant Johns, Ermanno Gherardi, Andrew Mark Scott
  • ANTIBODIES AGAINST HGF - RECEPTOR AND USES
    Publication number: 20150147274
    Abstract: Antibodies which are antagonists of the human HGF receptor (MET), wherein the antibodies specifically bind to amino acid residues 568-741 of human MET (SEQ ID No: 1) with high affinity.
    Type: Application
    Filed: November 30, 2012
    Publication date: May 28, 2015
    Inventors: Danielle Marie Di Cara, John McCafferty, Ermanno Gherardi, Anthony Richard Pope
  • Antibodies Directed to the Unprocessed Receptor Tyrosine Kinase c-Met
    Publication number: 20130171063
    Abstract: The present invention relates to antibodies that specifically bind to unprocessed c-Met present on the surface of tumor cells. These antibodies are useful in the diagnosis and treatment of cancer or as agents for delivering moieties to cancer cells. The antibodies of the present invention may also be used in therapy in combination with chemotherapeutics or anti-cancer agents.
    Type: Application
    Filed: June 1, 2011
    Publication date: July 4, 2013
    Inventors: Terrance Grant Johns, Ermanno Gherardi, Andrew Mark Scott
  • NK1 fragment of hepatocyte growth factor/scatter factor (HGF/SF) and variants thereof, and their use
    Patent number: 8232258
    Abstract: The present invention relates to variants of the NK1 fragment of the polypeptide growth factor HGF/SF which act as agonists of the MET receptor and their use. The agonists comprise at least one substitution at positions equivalent to 132, 134, 170 and 181 of full length HGF/SF and these substitutions provide a variant which shows scatter factor activity and induces DNA synthesis. In vivo the variants provide protection from liver damage in a model of acute liver failure.
    Type: Grant
    Filed: August 17, 2010
    Date of Patent: July 31, 2012
    Assignees: Cambridge Enterprise Limited, Medical Research Council
    Inventors: Ermanno Gherardi, Daniel Lietha, Thomas Leon Blundell, Dimitry Yurievich Chirgadze
  • NK1 FRAGMENT OF HEPATOCYTE GROWTH FACTOR/SCATTER FACTOR (HGF/SF) AND VARIANTS THEREOF, AND THEIR USE
    Publication number: 20110021612
    Abstract: The present invention relates to variants of the NK1 fragment of the polypeptide growth factor HGF/SF which act as agonists of the MET receptor and their use. The agonists comprise at least one substitution at positions equivalent to 132, 134, 170 and 181 of full length HGF/SF and these substitutions provide a variant which shows scatter factor activity and induces DNA synthesis. In vivo the variants provide protection from liver damage in a model of acute liver failure.
    Type: Application
    Filed: August 17, 2010
    Publication date: January 27, 2011
    Applicant: Medical Research Council
    Inventors: Ermanno Gherardi, Daniel Lietha, Thomas Leon Blundell, Dimitry Yurievich Chirgadze
  • Variants of the NK1 fragment of hepatocyte growth factor/scatter factor (HGF/SF) and their use
    Patent number: 7795214
    Abstract: Variants of the NK1 fragment of the polypeptide growth factor HGF/SF which act as agonists of the MET receptor and their use are disclosed. The agonists comprise at least one substitution at positions equivalent to 132, 134, 170 and 181 of full length HGF/SF (SEQ ID NO:2) and these substitutions provide variants which show scatter factor activity and induce DNA synthesis. In vivo, the variants provide protection from liver damage in a model of acute liver failure.
    Type: Grant
    Filed: January 26, 2007
    Date of Patent: September 14, 2010
    Assignees: Cambridge Enterprise Limited, Medical Research Council
    Inventors: Ermanno Gherardi, Daniel Lietha, Thomas Leon Blundell, Dimitry Yurievich Chirgadze
  • Soluble ectodomain fragments of MET and uses thereof
    Patent number: 7741051
    Abstract: The invention relates a fragment derived from the MET ectodomain which the inventors have found is capable, in monomer form, of binding to HGF/SF either in the presence or absence of heparin. The availability of soluble, monomeric forms of the MET receptor enabled studies of its solution properties and HGF/SF binding and provides an assay comprising the steps of (a) providing a MET ectodomain fragment; (b) providing an agent; and (c) determining the extent to which the agent interacts with said fragment.
    Type: Grant
    Filed: September 15, 2004
    Date of Patent: June 22, 2010
    Assignee: Medical Research Council
    Inventor: Ermanno Gherardi
  • NK1-BASED POLYPEPTIDES AND RELATED METHODS
    Publication number: 20090215686
    Abstract: The present invention includes various NK1-based polypeptides and polynucleotides, related compositions, methods of modulating Met activity in a cell, and related methods of treatment. Also, the present invention includes a method for designing an antagonist of a receptor tyrosine kinase from a receptor tyrosine kinase agonist.
    Type: Application
    Filed: March 5, 2008
    Publication date: August 27, 2009
    Inventors: Huaqiang Eric Xu, Ermanno Gherardi
  • VARIANTS OF THE NK1 FRAGMENT OF HEPATOCYTE GROWTH FACTOR/SCATTER FACTOR (HGF/SF) AND THEIR USE
    Publication number: 20080167224
    Abstract: Variants of the NK1 fragment of the polypeptide growth factor HGF/SF which act as agonists of the MET receptor and their use are disclosed. The agonists comprise at least one substitution at positions equivalent to 132, 134, 170 and 181 of full length HGF/SF (SEQ ID NO:2) and these substitutions provide variants which show scatter factor activity and induce DNA synthesis. In vivo, the variants provide protection from liver damage in a model of acute liver failure.
    Type: Application
    Filed: January 26, 2007
    Publication date: July 10, 2008
    Applicant: Medical Research Council
    Inventors: Ermanno Gherardi, Daniel Lietha, Thomas Leon Blundell, Dimitry Yurievich Chirgadze
  • Variants of the NK1 fragment of hepatocyte growth factor/scatter factor (HGF/SF) and their use
    Patent number: 7179786
    Abstract: Variants of the NK1 fragment of the polypeptide growth factor HGF/SF which act as agonists of the MET receptor and their use are disclosed. The agonists comprise at least one substitution at positions equivalent to 132, 134, 170 and 181 of full length HGF/SF (SEQ ID NO:2) and these substitutions provide variants which show scatter factor activity and induce DNA synthesis. In vivo, the variants provide protection from liver damage in a model of acute liver failure.
    Type: Grant
    Filed: April 29, 2002
    Date of Patent: February 20, 2007
    Assignee: Medical Research Council
    Inventors: Ermanno Gherardi, Daniel Lietha, Thomas Leon Blundell, Dimitry Yurievich Chirgadze
  • Soluble ectodomain fragments of met and uses thereof
    Publication number: 20070037209
    Abstract: The invention relates a fragment derived from the MET ectodomain which the inventors have found is capable, in monomer form, of binding to HGF/SF either in the presence or absence of heparin. The availability of soluble, monomeric forms of the MET receptor enabled studies of its solution properties and HGF/SF binding and provides an assay comprising the steps of (a) providing a MET ectodomain fragment; (b) providing an agent; and (c) determining the extent to which the agent interacts with said fragment.
    Type: Application
    Filed: September 15, 2004
    Publication date: February 15, 2007
    Inventor: Ermanno Gherardi
  • Nk1 fragment of hepatocyte growth factor/scatter factor (hgf/sf) and variants thereof,and their use
    Publication number: 20040236073
    Abstract: The present invention relates to variants of the NK1 fragment of the polypeptide growth factor HGF/SF which act as agonists of the MET receptor and their use. The agonists comprise at least one substitution at positions equivalent to 132, 134, 170 and 181 of full length HGF/SF and these substitutions provide a variant which shows scatter factor activity and induces DNA synthesis. In vivo the variants provide protection from liver damage in a model of acute liver failure.
    Type: Application
    Filed: April 29, 2004
    Publication date: November 25, 2004
    Inventors: Ermanno Gherardi, Daniel Lietha, Thomas Leon Blundell, Dimitry Yurievich Chirgadze
  • Relating to mutagenesis of nucleic acids
    Patent number: 6153745
    Abstract: The invention concerns novel compounds having defined structural formulae and methods of mutating a nucleic acid sequence, the method comprising replicating a template sequence in the presence of a nucleoside triphosphate analogue in accordance with the invention, so as to form non-identical copies of the template sequence comprising one or more nucleoside triphosphate analogue residues, and a kit for use in performing the method of the invention.
    Type: Grant
    Filed: July 6, 1998
    Date of Patent: November 28, 2000
    Assignee: Amersham Pharmacia Biotech UK Limited
    Inventors: David Williams, Daniel Brown, Manuella Carla Zaccolo, Ermanno Gherardi